false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
ITE 2024 Live
ITE 2024 Live - Session 2 (Diabetes, Lipids/Obesit ...
ITE 2024 Live - Session 2 (Diabetes, Lipids/Obesity, Adrenal, Thyroid)
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video focuses on the treatment of obesity using semaglutide, a GLP-1 receptor agonist known to promote weight loss, particularly in patients with a BMI of 27 or greater and related comorbidities like hypertension or type 2 diabetes. Recombinant leptin is more suitable for congenital leptin deficiency, while setanilatide is for type 2 diabetes, not specifically for obesity. The presentation also covers cases related to diabetes, lipids, obesity, and thyroid disorders, highlighting diagnostic tests, treatment options, and management strategies for conditions such as primary hyperaldosteronism and Graves' disease. It emphasizes the importance of genetic testing, proper dosing in pregnancy, and the significance of thyroid nodules. The discussion also delves into the differential diagnosis of hyperthyroidism, distinguishing between painless thyroiditis and factitious thyroiditis. The cases underscore the complexity of endocrine disorders and the need for thorough evaluation and personalized management. The presentation concludes by inviting questions from the audience and expressing gratitude for their participation.
Keywords
obesity treatment
semaglutide
GLP-1 receptor agonist
weight loss
BMI 27
hypertension
type 2 diabetes
recombinant leptin
congenital leptin deficiency
setanilatide
hyperthyroidism
×